Structural basis for AcrVA4 inhibition of specific CRISPR-Cas12a.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 31397669.
- Also identified by DOI 10.7554/eLife.49110 and PMC identifier 6711708.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
CRISPR-Cas systems provide bacteria and archaea with programmable immunity against mobile genetic elements. Evolutionary pressure by CRISPR-Cas has driven bacteriophage to evolve small protein inhibitors, anti-CRISPRs (Acrs), that block Cas enzyme function by wide-ranging mechanisms. We show here that the inhibitor AcrVA4 uses a previously undescribed strategy to recognize the <i>L. bacterium</i> Cas12a (LbCas12a) pre-crRNA processing nuclease, forming a Cas12a dimer, and allosterically inhibiting DNA binding. The <i>Ac. species</i> Cas12a (AsCas12a) enzyme, widely used for genome editing applications, contains an ancestral helical bundle that blocks AcrVA4 binding and allows it to escape anti-CRISPR recognition. Using biochemical, microbiological, and human cell editing experiments, we show that Cas12a orthologs can be rendered either sensitive or resistant to AcrVA4 through rational structural engineering informed by evolution. Together, these findings explain a new mode of CRISPR-Cas inhibition and illustrate how structural variability in Cas effectors can drive opportunistic co-evolution of inhibitors by bacteriophage.
Medical subject headings
- Acidaminococcus
- Bacteriophages
- CRISPR-Cas Systems
- Eubacteriales
- Enzyme Inhibitors
- Host-Parasite Interactions
- Viral Proteins